Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | KRAS | P01116 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.36 |
| ▸ | NAMPT | P43490 | 7/20 | 0.35 |
| ▸ | MMP13 | P45452 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.33 |
| ▸ | F13A1 | P00488 | 1/20 | 0.33 |
| ▸ | TGM2 | P21980 | 1/20 | 0.33 |
| ▸ | TGM1 | P22735 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26176372 | 1.00 | PTPN11 (0.41) | PTPN11PKMKRASGPR119NAMPT | |
| SCHEMBL20111995 | 0.79 | HTR6 (0.57) | PTPN11GPR119HTR6JAK1 | |
| SCHEMBL30400441 | 0.77 | HTR6 (0.41) | GPR119MMP13HTR6MMP2 | |
| SCHEMBL26176387 | 0.77 | HTR6 (0.41) | GPR119MMP13HTR6MMP2 | |
| SCHEMBL20111957 | 0.77 | SCN9A (0.44) | GPR119MMP13KMT2AJAK2JAK1 | |
| SCHEMBL30400627 | 0.72 | MAPK1 (0.43) | PKMNAMPTJAK2JAK1 | |
| SCHEMBL26176370 | 0.72 | MAPK1 (0.43) | PKMNAMPTJAK2JAK1 | |
| SCHEMBL23247749 | 0.72 | PTPN11 (0.41) | PTPN11KRASGPR119NAMPTMMP13 | |
| SCHEMBL30280405 | 0.71 | ESR2 (0.44) | PTPN11GPR119NAMPTMMP13MEN1 | |
| SCHEMBL22324681 | 0.69 | PTPN11 (0.47) | PTPN11GPR119MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4415817-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AS DYRK1A INHIBITORS | BioSplice Therapeutics, Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2023-06-22 | — | — | US | disclosed |
| WO-2023064349-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AS DYRK1A INHIBITORS | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK1B, DYRK2 | PTPN11 634/4885PKM 743/4885KRAS 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.